Trial Profile
A Randomized, Parallel, Double-Blind, Placebo-Controlled, Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Background of Methotrexate.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs TRU 015 (Primary)
- Indications Rheumatoid arthritis
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Pfizer
- 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database.
- 15 Jun 2013 Results for part A presented at the 14th Annual Congress of the European League Against Rheumatism.
- 14 Jun 2010 Primary endpoint 'American College of Rheumatology 50% response criteria' has not been met.